Ancylostomiasis
disease diseaseOn this page
Also known as Ancylostoma caused disease or disorderAncylostoma disease or disorderAncylostoma duodenale infectionAncylostoma infectious diseasehookworm infection
Summary
Ancylostomiasis (MONDO:0005645) is a disease and 33 clinical trials. Top therapeutic interventions include mebendazole, albendazole, and moxidectin. A subtype of Rhabditida infectious disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Prevalence: Unknown (Worldwide)
- Clinical trials: 33
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | ancylostomiasis |
| Mondo ID | MONDO:0005645 |
| EFO | EFO:0007145 |
| MeSH | D000724 |
| Orphanet | 78 |
| DOID | DOID:12841 |
| ICD-10-CM | B76.0 |
| ICD-11 | 1542252776 |
| NCIT | C35805 |
| SNOMED CT | 63479002 |
| UMLS | C0002831 |
| MedGen | 1522 |
| GARD | 0009742 |
| MedDRA | 10002255, 10020376 |
| Is cancer (heuristic) | no |
Also known as: Ancylostoma caused disease or disorder · Ancylostoma disease or disorder · Ancylostoma duodenale infection · Ancylostoma infectious disease · hookworm infection
Disease family
This is a subtype of Rhabditida infectious disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › parasitic infectious disease › helminthiasis › Nematoda infectious disease › Rhabditida infectious disease › ancylostomiasis
Related subtypes (11): thelaziasis, Ascaridida infectious disease, enterobiasis, mansonelliasis, oesophagostomiasis, setariasis, strongyloidiasis, trichostrongylosis, dirofilariasis, dracunculiasis, onchocerciasis
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 33.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE1 | 11 |
| PHASE2 | 7 |
| Not specified | 7 |
| PHASE3 | 4 |
| PHASE4 | 3 |
| PHASE2/PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT07145736 | PHASE4 | RECRUITING | Moxidectin Versus Ivermectin as Mass Drug Administration for the Control of Onchocerciasis and Other Neglected Tropical Diseases |
| NCT03261596 | PHASE4 | WITHDRAWN | Mebendazole Study Against Hookworm Infections in Children and Adolescents in Ghana |
| NCT03278431 | PHASE4 | COMPLETED | Triple Combinations Against Hookworm Infections in Lao |
| NCT06736691 | PHASE3 | ENROLLING_BY_INVITATION | Efficacy and Safety of Emodepside in Participants With Soil-transmitted Helminth Infections |
| NCT06800248 | PHASE3 | NOT_YET_RECRUITING | Efficacy and Safety of Emodepside in Participants With Soil-transmitted Helminth Infections |
| NCT04700423 | PHASE2/PHASE3 | COMPLETED | Efficacy and Safety of MOX/ALB vs. IVM/ALB Co-administration |
| NCT04726969 | PHASE3 | COMPLETED | Efficacy and Safety of MOX/ALB Co-administration |
| NCT06188715 | PHASE3 | COMPLETED | Efficacy and Safety of Moxidectin-Albendazole Co-administration in SAC |
| NCT03172975 | PHASE2 | COMPLETED | Efficacy of Na-GST-1/Alhydrogel Hookworm Vaccine Assessed by Controlled Challenge Infection |
| NCT03527745 | PHASE2 | COMPLETED | Albendazole Dose Finding and Pharmacokinetics in Children and Adults |
| NCT03995680 | PHASE2 | COMPLETED | Efficacy and Safety of a New Chewable Versus the Swallowable Tablet of Mebendazole Against Hookworm |
| NCT05017194 | PHASE2 | COMPLETED | Efficacy and Safety of Emodepside in Adults Infected With Trichuris Trichiura and Hookworm |
| NCT05538767 | PHASE2 | COMPLETED | Efficacy and Safety of Emodepside in Adolescents and Adults Infected With Hookworm |
| NCT06184399 | PHASE2 | COMPLETED | Efficacy, Safety and Acceptability of Ivermectin ODT in PSAC |
| NCT06720259 | PHASE2 | COMPLETED | Efficacy and Safety of Oxantel Pamoate in Children Infected With Trichuris Trichiura |
| NCT01940757 | PHASE1 | RECRUITING | Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae |
| NCT00120081 | PHASE1 | COMPLETED | Study of Na-ASP-2 Human Hookworm Vaccine in Healthy Adults Without Evidence of Hookworm Infection |
| NCT00473967 | PHASE1 | TERMINATED | Phase 1 Trial of Na-ASP-2 Hookworm Vaccine in Previously Infected Brazilian Adults |
| NCT01261130 | PHASE1 | COMPLETED | Safety and Immunogenicity of a Human Hookworm Candidate Vaccine With or Without Additional Adjuvant in Brazilian Adults |
| NCT01385189 | PHASE1 | COMPLETED | Safety and Immunogenicity of a Human Hookworm Candidate Vaccine With Different Doses of a Novel Adjuvant |
| NCT01717950 | PHASE1 | COMPLETED | Safety and Immunogenicity of the Na-APR-1 Hookworm Vaccine in Healthy Adults |
| NCT02126462 | PHASE1 | COMPLETED | Safety and Immunogenicity of Co-Administered Hookworm Vaccine Candidates Na-GST-1 and Na-APR-1 in Gabonese Adults |
| NCT02143518 | PHASE1 | COMPLETED | Safety and Immunogenicity Study of Na-GST-1 With or Without CpG |
| NCT02476773 | PHASE1 | COMPLETED | Study of Na-APR-1 (M74)/Alhydrogel® Co-administered With Na-GST-1/Alhydrogel in Brazilian Adults |
| NCT02839161 | PHASE1 | COMPLETED | Study of Co-administered Na-APR-1 (M74) and Na-GST-1 in Gabonese Children |
| NCT03373214 | PHASE1 | COMPLETED | Na-GST-1/Alhydrogel With or Without CpG 10104 in Gabonese Adults |
| NCT00207753 | Not specified | COMPLETED | Effectiveness of Combined Albendazole and Ivermectin Treatment for Intestinal Worm Infections |
| NCT00603889 | Not specified | COMPLETED | Development of a Skin Test for the Na-ASP-2 Hookworm Antigen |
| NCT00939198 | Not specified | COMPLETED | Prevalence of Hookworm Infection and Community Preparedness for Hookworm Vaccine Trials in Endemic Areas of Brazil |
| NCT01163877 | Not specified | COMPLETED | Iron Absorption and Utilization in Adolescents Infected With Malaria Parasites, Hookworms or Schistosoma |
| NCT02262403 | Not specified | UNKNOWN | Hookworm Immune Regulation Project |
| NCT04227834 | Not specified | UNKNOWN | Soil-transmitted Helminth Reinfection Rates After Single and Repeated School Hygiene Education |
| NCT05914363 | Not specified | COMPLETED | Evaluating Impact of Improved Floors on Health |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| MEBENDAZOLE | 4 | 6 |
| ALBENDAZOLE | 4 | 5 |
| MOXIDECTIN | 4 | 3 |
| PYRANTEL | 4 | 3 |
| HEPATITIS B VIRUS HBSAG SURFACE PROTEIN ANTIGEN | 4 | 2 |
| IVERMECTIN | 4 | 2 |
| OXANTEL | 2 | 4 |
| EMODEPSIDE | 2 | 2 |
| GLA-AF | 2 | 2 |
| CHEMBL4782609 | 0 | 3 |
| CHEMBL5280985 | 0 | 3 |
| CHEMBL263291 | 0 | 2 |
| CHEMBL4082099 | 0 | 2 |
| CHEMBL4788951 | 0 | 2 |
| CHEMBL283807 | 0 | 2 |